The Photon Factory effect

How a small team of researchers became one of New Zealand’s most prolific innovation engines.

Cather SImpson wearing a black balzer, blue scarf and white shirt, standing in front of a grey wall, smiling.
Professor Cather Simpson

When it comes to entrepreneurship, commercial impact and real-world outcomes, the Photon Factory shines brightly.

What started out in 2009 as a multidisciplinary research group founded by Professor of Physics and Chemical Science Cather Simpson has become a veritable production line of spinouts which have used lasers to identify cattle sperm, detect cancer and even destroy varroa mites on bees.

“I’ve found that having an impact like that is very, very different, but just as important as understanding something fundamental that winds up in a textbook,” says Cather.

The sheer volume of grants secured by Photon Factory researchers highlights the alignment of their research with Government objectives, such as the current Science Investment Plan which directs investment toward opportunities with the greatest potential to drive economic growth and long-term prosperity.

Since 2012, the Photon Factory has attracted government grants totalling around $30 million, almost $23 million of which was secured by Cather’s team for fundamental and applied research.

“The group was extraordinarily effective at communicating that we are a community of scholars and inventors trying to solve really important, exciting problems,” she says. “We were awarded our first Ministry of Business, Innovation and Employment (MBIE) grant, and that set us off on a steep, industry-facing, entrepreneurial trajectory.”

Turning photonics into global health solutions

The first of the spinouts was Engender Technologies, which used photonics to separate male and female sperm cells in cattle to solve the problem of gender selection, and was acquired by the world-leading animal genetics company CRV International in 2018.

Then came Orbis Diagnostics, which started out in 2016 evaluating the complex components in milk to improve quality, and then morphed into an immunity testing business during Covid, before developing a world-first Hepatitis B testing kit based on a simple pinprick of blood.

We’ve been tasked to be bold, and I think the time is right.

Cather Simpson

With 50 percent of the world’s liver cancers caused by the deadly virus, Orbis is attacking a massive global health problem as it prepares for a pivotal US clinical trial that will hopefully pave the way for FDA approval and launch into a market estimated to be worth US$1.5 billion.

“If it all goes the way it’s supposed to, we’ll enter the US market in 2029,” says Cather as Orbis CEO. “We’re well past the research stage. We’re fully in development doing key verification and validation studies.”

Orbis has also attracted the attention of the US Hepatitis B Foundation, and CEO Dr Chari Cohen says their diagnostic tool could help eliminate hepatitis B worldwide.

“Having a triple panel point of care diagnostic test for hepatitis B would be transformational, overcoming a significant barrier that would allow us to test, diagnose, and link millions more people with medical care and treatment that could save their lives.”

A common feature of all Photon Factory start-ups has been the injection of seed capital from the University’s commercialisation arm, UniServices, and many have also been backed by the Asia-Pacific deep-tech investment firm Pacific Channel, founded by University alumnus Brent Ogilvie.

“The Photon Factory was intentionally outwardly facing from the very beginning,” says Cather, who ran a programme to train emerging researchers on how to manage research contracts. “So it was really important early on that we achieved what we said we were going to achieve.”

More recently, Cather has been appointed to the board of the New Zealand Institute for Advanced Technology (NZIAT), a new Public Research Organisation set up as part of the 2025 science system reforms. The NZIAT is designed to bring researchers, industry and investors closer together, with a clear focus on translating cutting-edge science into real-world impact.

“We’ve been tasked to be bold, and I think the time is right,” she says. “It’s not the No 8 wire mentality that’s the problem, it’s the translation to commercial impact that we need to build on. We need to capitalise better on our cleverness.”

However, she says it’s also important not to lose sight of the fundamental research that forms the bedrock of the Photon Factory’s success.

“We need to make sure as a country that we invest across the pipeline or else we’ll narrow the funnel at the entry point. The risk is that we effectively stop entrepreneurial activity right at the start when it’s a research idea.”

Lighting the way in cancer detection

Michél Nieuwoudt, sitting at a desk, smiling, wearing a grey cardigan and flower-patterned shirt.
Dr Michél Nieuwoudt

As a Senior Research Fellow in the School of Chemical Sciences, Dr Michél Nieuwoudt is full of praise for the collegial environment that exists within the Photon Factory.

“This freedom to interact and learn and give advice, that’s what makes this place grow. It’s the interaction between resources and the symbiosis of people wanting to do things together.”

It was while she was working on a project using what’s known as Raman spectroscopy to monitor farm milk quality for Fonterra that she thought of applying the same technology to skin cancer. After all, “skin is a complex biological material; milk is a complex biological material,” says Michél.

Another motivation was the early death of a relative from melanoma. “There are more people that die from melanoma than road deaths every year. So, I was like, well, we can certainly do something about that.”

Initially supported by a $1 million MBIE Smart Ideas grant, a research team rapidly developed a device that has proved superior to existing skin analytics like mole mapping.

“Other skin analytic technologies require unnecessary biopsies on lesions, whereas our device is much more accurate. So we thought, ‘this is cool, let’s try and form a spinout company,’ and that’s what we did.”

This freedom to interact and learn and give advice, that’s what makes this place grow.

Michél Nieuwoudt

Luminoma has so far raised more than $5 million from investors including Bridgewest Ventures, Pacific Channel, and the government to get the company off the ground. “You need investors, and someone to believe enough in your product,” says Michél. “It’s a leap of faith for them, so we work really hard to say, ‘we’re going to make this work for you’.”

Fast forward to 2026, and Luminoma is now undertaking a pilot study at six different clinics throughout Auckland to build a new algorithm. It’s also raising fresh capital to develop a hand-held wand called LumAssure™ that could reach the market within three years.

There’s also a new collaboration with the world-renowned Mayo Clinic which Michél says will broaden their testing to a wider range of skin types and will be critical for entry into the United States.

“They’re excited by what our device can do that others can’t, and they see a lot of possibilities.” And while some populations don’t have the same challenges with melanoma, the skin problems.

“It’s very hard sometimes to distinguish psoriasis and eczema in adults and children, but our device can do this accurately. It would just be a non-invasive 10 second measurement, point and shoot, to get the outcome.”

As Luminoma’s chief scientific officer, Michél was recognised as a finalist for the 2025 KiwiNet Researcher Entrepreneur Award and says her passion for the project is driven by all the grateful patients who’ve had measurements taken in their clinic.

“They’re so happy that we’re doing this,and so it inspires us even more.”

Lasers, bees and the next wave of spinouts

Dr Francesco Merola with the Beam Agritech team at the Bioeconomy Science Institute in Ruakura. They are standing in an office environment, wearing black t-shirts with bees and lasers on them.
Dr Francesco Merola (second from left) with the Smart Ideas team at the Bioeconomy Science Institute in Ruakura.

The idea of using lasers to kill the invasive varroa mite that destroys bee colonies worldwide had been bandied about within the Photon Factory for several years before Dr Francesco Merola joined the Faculty of Science as a Senior Research Fellow in 2022.

However, the cheerful Italian physicist was the first to embrace the concept of developing the world’s first ‘intelligent beehive’ with a project that was initially supported by a $1 million MBIE Smart Ideas grant in partnership with the Bee Biology & Productivity Team at Plant & Food Research (now the Bioeconomy Science Institute).

“They believed in us and we are now in the third year of this amazing Smart Ideas project,” says Francesco.

Using Plant & Food’s PC2 Physical Containment lab in Hamilton, the  researchers have developed a prototype device that uses a combination of cameras and lasers to achieve their objective.

“We found the right laser parameters in terms of power, exposure time and frequency. The dose is delivered to the mites and we are able to kill them with the lasers without harming the bees.”

A key challenge is to develop an algorithm, using machine learning, to detect which bees carry the mites and intercept them before they enter the hive and harm the brood. “The algorithm will inform the laser to fire when the bee is in the right position.”

The aim is to design a device that’s cost effective for beekeepers who currently use relatively cheap pesticides to treat the varroa. But the work can be time consuming when they often have to travel several hours to treat hives multiple times in remote locations.

I want to make something that’s good for the environment as well. If we could reduce the use of chemicals, not just in the hives but in general, I think it would be a better world with less pesticides.

Francesco Merola

“Another key challenge is to get the technology out of the lab and working in the hive at the right price,” says Francesco.

Using relatively cheap micro cameras and 3D printed plastic boxes will contain costs, and the price of lasers continues to fall, but the devices will also provide added value.

“This technology can also provide other information to beekeepers like mite and bee counting. We can also monitor temperature and humidity, assess bee behaviour, and analyse the pollen and honey quality automatically.”

Meanwhile, the pathway to commercialisation has started to accelerate with the formation of a company called Beam Agritech which has initially raised $1.3 million in seed capital, loans and grants to deliver a minimum viable product within 18 months.

“Our big milestone is to have something that we can put on the market and sell. This is our dream,” says Francesco, although it’s not just about increasing productivity or making money.

“I want to make something that’s good for the environment as well. If we could reduce the use of chemicals, not just in the hives but in general, I think it would be abetter world with less pesticides.”

Claude Aguergaray sitting at a table in a science lab that has science apparatus in it. He is wearing a white shirt and glasses.
Dr Claude Aguergaray

Yet another Photon Factory spinout is Probentis, established by Dr Claude Aguergaray to develop a laser-driven diagnostic tool that robotic surgical platforms could use to accurately identify cancer cells in real time for prostate surgery.

“Along with our clinical advisers, we have identified the right performance metrics and impact on patient management.”

After eight years of research, the team has demonstrated highly accurate prostate cancer detection using measurements that take only a few seconds and achieve performance that exceeds MRI and standard pathology.

“We’re focused on developing a machine to ensure that cancer isn’t missed during surgery. Currently, if the machine tells a clinician that an area is benign, we are 96 percent sure that it is actually benign,” says Claude. “They start to be numbers that would be useful for a machine to be implemented in real life.”

Clinical trials under way in 2026 are designed to predict whether prostate cancer is present without the need for invasive biopsies, and further trials in 2027 will help determine surgical margins which could lead to better patient outcomes. 

“You have to satisfy the health insurance companies and the hospitals. To maximise the chances of adoption for a new medtech device, it needs to show better patient outcomes at a lower cost.”

We’re focused on developing a machine to ensure that cancer isn’t missed during surgery.

Claude Aguergaray

Up until now, the research has been funded by MBIE Smart Ideas grants worth $2.33 million, with additional support from Te Tītoki Mataora – MedTech Research Translator, and the Te Whai Ao – Dodd-Walls Centre. Probentis was also kick-started with seed capital and expertise from UniServices.

Looking ahead, commercial advisers will help raise capital and navigate the regulatory environment for a market-ready product while Claude plans the next clinical translation trials. “All these pieces of the puzzle will answer the broader question about clinical utility.”

As the recently appointed director of the Photon Factory and Microfabrication Facility, Claude is also guiding the research Platform into a new phase where it provides a suite of instruments that enables a wide range of high-quality research – and ensures alignment with the University’s new ‘Frontier Technologies’ Signature Research Area and government priorities, including those of the NZIAT.

“We aim to support science that is relevant to New Zealand, and to current and future researchers.” And while the core capabilities of micromachining, surface processing and sensing remain, new frontiers will be explored in areas like space and conservation work – in addition to existing commitments to the agritech and health sectors.

“These are areas in which New Zealand has real strengths and form an important part of our economy. At the same time, the health challenges we face are often shared globally which creates opportunities for our solutions to have international impact.”